SULFADIAZINE ZINC

Details

Stereochemistry	ACHIRAL
Molecular Formula	2C10H9N4O2S.Zn
Molecular Weight	563.947
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

[Zn++].NC1=CC=C(C=C1)S(=O)(=O)[N-]C2=NC=CC=N2.NC3=CC=C(C=C3)S(=O)(=O)[N-]C4=NC=CC=N4

InChI

InChIKey=RXXROIWDLGTUIN-UHFFFAOYSA-N

InChI=1S/2C10H9N4O2S.Zn/c2*11-8-2-4-9(5-3-8)17(15,16)14-10-12-6-1-7-13-10;/h2*1-7H,11H2;/q2*-1;+2

HIDE SMILES / InChI

Molecular Formula	Zn
Molecular Weight	65.409
Charge	2
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	C10H10N4O2S
Molecular Weight	250.277
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: http://www.drugbank.ca/drugs/DB00359
Curator's Comment: Description was created based on several sources, including https://www.drugs.com/dosage/sulfadiazine.html

Sulfadiazine is a sulfonamide antibiotic. The sulfonamides are synthetic bacteriostatic antibiotics with a wide spectrum against most gram-positive and many gram-negative organisms. However, many strains of an individual species may be resistant. Sulfonamides inhibit multiplication of bacteria by acting as competitive inhibitors of p-aminobenzoic acid in the folic acid metabolism cycle. Bacterial sensitivity is the same for the various sulfonamides, and resistance to one sulfonamide indicates resistance to all. Most sulfonamides are readily absorbed orally. However, parenteral administration is difficult, since the soluble sulfonamide salts are highly alkaline and irritating to the tissues. The sulfonamides are widely distributed throughout all tissues. High levels are achieved in pleural, peritoneal, synovial, and ocular fluids. Although these drugs are no longer used to treat meningitis, CSF levels are high in meningeal infections. Their antibacterial action is inhibited by pus. Sulfadiazine is a competitive inhibitor of the bacterial enzyme dihydropteroate synthetase. This enzyme is needed for the proper processing of para-aminobenzoic acid (PABA) which is essential for folic acid synthesis. The inhibited reaction is necessary in these organisms for the synthesis of folic acid. Used for the treatment of rheumatic fever and meningococcal meningitis.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Potency
Serine/threonine-protein kinase Aurora-A 37 Target ID: CHEMBL4722 Sources: https://www.ncbi.nlm.nih.gov/pubmed/18457385	Inhibitor 8504	21.0 µM [IC50]
Toxoplasma gondii 10 Target ID: CHEMBL612888 Sources: https://www.ncbi.nlm.nih.gov/pubmed/18563892	Inhibitor 8504	41.2 µM [IC50]
Escherichia coli 82 Target ID: CHEMBL354 Sources: https://www.ncbi.nlm.nih.gov/pubmed/17719222	Inhibitor 8504
Dihydropteroate synthetase 10 Target ID: CHEMBL2013 Sources: http://www.drugbank.ca/drugs/DB00359	Inhibitor 8504
Bacterial dihydropteroate synthase 44 Target ID: CHEMBL2364668 Sources: http://www.genome.jp/dbget-bin/www_bget?D00587	Inhibitor 8504	4.2 µM [IC50]

Conditions

Condition	Modality	Highest Phase	Product
Toxoplasmosis encephalitis 3 Sources: https://www.drugs.com/pro/sulfadiazine.html	Curative	Approved 8583	Sulfadiazine Approved Use Sulfadiazine tablets USP are indicated in the following conditions: Chancroid Trachoma Inclusion conjunctivitis Nocardiosis Urinary tract infections (primarily pyelonephritis, pyelitis and cystitis) in the absence of obstructive uropathy or foreign bodies, when these infections are caused by susceptible strains of the following organisms: Escherichia coli, Klebsiella species, Enterobacter species, Staphylococcus aureus, Proteus mirabilis and P. vulgaris. Sulfadiazine should be used for urinary tract infections only after use of more soluble sulfonamides has been unsuccessful. Toxoplasmosis encephalitis in patients with and without acquired immunodeficiency syndrome, as adjunctive therapy with pyrimethamine. Malaria due to chloroquine-resistant strains of Plasmodium falciparum, when used as adjunctive therapy. Prophylaxis of meningococcal meningitis when sulfonamide-sensitive group A strains are known to prevail in family groups or larger closed populations (the prophylactic usefulness of sulfonamides when group B or C infections are prevalent is not proved and may be harmful in closed population groups). Meningococcal meningitis, when the organism has been demonstrated to be susceptible. Acute otitis media due to Haemophilusinfluenzae, when used concomitantly with adequate doses of penicillin. Prophylaxis against recurrences of rheumatic fever, as an alternative to penicillin. H. influenzae meningitis, as adjunctive therapy with parental streptomycin. Launch Date 1994
Urinary tract infections 207 Sources: https://www.drugs.com/pro/sulfadiazine.html	Curative	Approved 8583	Sulfadiazine Approved Use Sulfadiazine tablets USP are indicated in the following conditions: Chancroid Trachoma Inclusion conjunctivitis Nocardiosis Urinary tract infections (primarily pyelonephritis, pyelitis and cystitis) in the absence of obstructive uropathy or foreign bodies, when these infections are caused by susceptible strains of the following organisms: Escherichia coli, Klebsiella species, Enterobacter species, Staphylococcus aureus, Proteus mirabilis and P. vulgaris. Sulfadiazine should be used for urinary tract infections only after use of more soluble sulfonamides has been unsuccessful. Toxoplasmosis encephalitis in patients with and without acquired immunodeficiency syndrome, as adjunctive therapy with pyrimethamine. Malaria due to chloroquine-resistant strains of Plasmodium falciparum, when used as adjunctive therapy. Prophylaxis of meningococcal meningitis when sulfonamide-sensitive group A strains are known to prevail in family groups or larger closed populations (the prophylactic usefulness of sulfonamides when group B or C infections are prevalent is not proved and may be harmful in closed population groups). Meningococcal meningitis, when the organism has been demonstrated to be susceptible. Acute otitis media due to Haemophilusinfluenzae, when used concomitantly with adequate doses of penicillin. Prophylaxis against recurrences of rheumatic fever, as an alternative to penicillin. H. influenzae meningitis, as adjunctive therapy with parental streptomycin. Launch Date 1994
Malaria 96 Sources: https://www.drugs.com/pro/sulfadiazine.html	Curative	Approved 8583	Sulfadiazine Approved Use Sulfadiazine tablets USP are indicated in the following conditions: Chancroid Trachoma Inclusion conjunctivitis Nocardiosis Urinary tract infections (primarily pyelonephritis, pyelitis and cystitis) in the absence of obstructive uropathy or foreign bodies, when these infections are caused by susceptible strains of the following organisms: Escherichia coli, Klebsiella species, Enterobacter species, Staphylococcus aureus, Proteus mirabilis and P. vulgaris. Sulfadiazine should be used for urinary tract infections only after use of more soluble sulfonamides has been unsuccessful. Toxoplasmosis encephalitis in patients with and without acquired immunodeficiency syndrome, as adjunctive therapy with pyrimethamine. Malaria due to chloroquine-resistant strains of Plasmodium falciparum, when used as adjunctive therapy. Prophylaxis of meningococcal meningitis when sulfonamide-sensitive group A strains are known to prevail in family groups or larger closed populations (the prophylactic usefulness of sulfonamides when group B or C infections are prevalent is not proved and may be harmful in closed population groups). Meningococcal meningitis, when the organism has been demonstrated to be susceptible. Acute otitis media due to Haemophilusinfluenzae, when used concomitantly with adequate doses of penicillin. Prophylaxis against recurrences of rheumatic fever, as an alternative to penicillin. H. influenzae meningitis, as adjunctive therapy with parental streptomycin. Launch Date 1994

C_max

Value	Dose	Co-administered	Analyte	Population
84.9 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/14742225/	2 g 2 times / day steady-state, oral dose: 2 g route of administration: Oral experiment type: STEADY-STATE co-administered:		SULFADIAZINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED

AUC

Value	Dose	Co-administered	Analyte	Population
1.247 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/14742225/	2 g 2 times / day steady-state, oral dose: 2 g route of administration: Oral experiment type: STEADY-STATE co-administered:		SULFADIAZINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED

T_1/2

Value	Dose	Co-administered	Analyte	Population
11.9 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/14742225/	2 g 2 times / day steady-state, oral dose: 2 g route of administration: Oral experiment type: STEADY-STATE co-administered:		SULFADIAZINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED

Doses

Dose	Population	Adverse events
4 g 1 times / day steady, oral Recommended Dose: 4 g, 1 times / day Route: oral Route: steady Dose: 4 g, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/12095805	unhealthy, 16 - 80 Health Status: unhealthy Age Group: 16 - 80 Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/12095805	Disc. AE: Stenocardia, Distress gastrointestinal... Other AEs: Thrombopenia, Creatinine serum increased... AEs leading to discontinuation/dose reduction: Stenocardia (grade 3, 5%) Distress gastrointestinal (grade 3, 5%) Skin rash (grade 3, 5%) Other AEs: Thrombopenia (9%) Creatinine serum increased (5%) Elevated liver enzyme levels (5%) Malaise (23%) Diarrhea (5%) Sources: https://pubmed.ncbi.nlm.nih.gov/12095805
1 g 4 times / day steady, oral Recommended Dose: 1 g, 4 times / day Route: oral Route: steady Dose: 1 g, 4 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/25411350	unhealthy, 29.81 Health Status: unhealthy Age Group: 29.81 Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/25411350	Disc. AE: Stevens Johnson syndrome, Thrombocytopenia... Other AEs: Skin rash, Neutropenia... AEs leading to discontinuation/dose reduction: Stevens Johnson syndrome (grade 3, 1.16%) Thrombocytopenia (grade 4, 25%) Major bleed (grade 4, 25%) Other AEs: Skin rash (1.16%) Neutropenia (18.75%) Febrile neutropenia (1.16%) Sources: https://pubmed.ncbi.nlm.nih.gov/25411350
6 g 1 times / day steady, oral Recommended Dose: 6 g, 1 times / day Route: oral Route: steady Dose: 6 g, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/1428784	unhealthy, 33.8 Health Status: unhealthy Age Group: 33.8 Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/1428784	Disc. AE: Skin rash, Neutropenia... AEs leading to discontinuation/dose reduction: Skin rash (grade 3, 17.24%) Neutropenia (grade 3, 3.45%) Acute renal failure (grade 3, 6.9%) Sources: https://pubmed.ncbi.nlm.nih.gov/1428784

AEs

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
substrate 1946	substrate 1193

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
OAT3 747	CYP2C8 810 P-gp 2052

Drug as perpetrator

Target	Modality	Activity	Metabolite	Clinical evidence
OAT3 749	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/29307856/	yes [IC50 6.65 uM]

Drug as victim

Target	Modality	Activity
CYP3A4 1946	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/15843491/	unlikely
CYP2C8 810	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/26721703/	yes
CYP2C9 1193	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/15843491/	yes
P-gp 2052	substrate 4014 Sources: https://link.springer.com/article/10.1007%2Fs00204-018-2209-9	yes

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:9328	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:9328
ChemicalBook	CB4166214	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB4166214
eMolecules	474308	https://www.emolecules.com/cgi-bin/more?vid=474308
MolPort	MolPort-000-629-738	https://www.molport.com/shop/molecule-link/MolPort-000-629-738
MolPort	MolPort-003-986-619	https://www.molport.com/shop/molecule-link/MolPort-003-986-619
MolPort	MolPort-028-603-008	https://www.molport.com/shop/molecule-link/MolPort-028-603-008
Selleck Chemicals	Sulfadiazine	http://www.selleckchem.com/products/Sulfadiazine.html
ZINC	ZINC000000120319	http://zinc15.docking.org/substances/ZINC000000120319

PubMed

Title	Date	PubMed
Outbreak of serogroup W135 meningococcal disease after the Hajj pilgrimage, Europe, 2000.	2002-08	12141959
Complete osseous regeneration of a large skull defect in a patient with cutis aplasia: a conservative approach.	2002-07	12140410
An update on current practices in the management of ocular toxoplasmosis.	2002-07	12095816
A prospective, randomized trial of pyrimethamine and azithromycin vs pyrimethamine and sulfadiazine for the treatment of ocular toxoplasmosis.	2002-07	12095805
An infection-preventing bilayered collagen membrane containing antibiotic-loaded hyaluronan microparticles: physical and biological properties.	2002-07	12081522
[Topical agents used in the treatment of burns].	2002-06-20	12070926
The effectiveness of processed grapefruit-seed extract as an antibacterial agent: I. An in vitro agar assay.	2002-06	12165190
Anal canal amputation and necrosis of the anal sphinchter due to electric current injury.	2002-06	12137454
Laminin modified infection-preventing collagen membrane containing silver sulfadiazine-hyaluronan microparticles.	2002-06	12072108
In vitro activities of pentamidine, pyrimethamine, trimethoprim, and sulfonamides against Aspergillus species.	2002-06	12019133
Unsuspected Toxoplasma gondii empyema in a bone marrow transplant recipient.	2002-05-01	11941570
Randomized phase II trial of atovaquone with pyrimethamine or sulfadiazine for treatment of toxoplasmic encephalitis in patients with acquired immunodeficiency syndrome: ACTG 237/ANRS 039 Study. AIDS Clinical Trials Group 237/Agence Nationale de Recherche sur le SIDA, Essai 039.	2002-05-01	11941551
[Glanders--a potential disease for biological warfare in humans and animals].	2002-05	12170562
Folate deficiency during treatment with orally administered folic acid, sulphadiazine and pyrimethamine in a horse with suspected equine protozoal myeloencephalitis (EPM).	2002-05	12108754
Silver. 2: Toxicity in mammals and how its products aid wound repair.	2002-05	12055941
Confocal laser microscopic observation of glycocalyx production by Staphylococcus aureus in vitro.	2002-05	12007722
Flamazine is not a debriding agent.	2002-04-11	11942317
Quantification of veterinary antibiotics (sulfonamides and trimethoprim) in animal manure by liquid chromatography-mass spectrometry.	2002-04-05	12064522
New simple liquid chromatographic method for the determination of trimethoprim, sulfadiazine and N4-acetylsulfadiazine in plasma of broilers.	2002-04-05	11996491
Submaxillary adenopathy as sole manifestation of toxoplasmosis: case report and literature review.	2002-04	12019742
Prevalence of moderate penicillin resistant invasive Neisseria meningitidis infection in Scotland, 1994-9.	2002-04	12002531
Transfer and distribution profiles of dietary sulphonamides in the tissues of the laying hen.	2002-04	11962694
Control of wound infections using a bilayer chitosan wound dressing with sustainable antibiotic delivery.	2002-03-05	11774301
Silver-coated endotracheal tubes associated with reduced bacterial burden in the lungs of mechanically ventilated dogs.	2002-03	11888974
Is a silver coating a silver lining?	2002-03	11888943
Iminodibenzyl as a novel coupling agent for the spectrophotometric determination of sulfonamide derivatives.	2002-03	11880002
[Increased serum and urinary levels of silver during treatment with topical silver sulfadiazine].	2002-02	11937961
[Congenital toxoplasmosis: prevention in the pregnant woman and management of the neonate].	2002-02	11915504
Comparison of propolis skin cream to silver sulfadiazine: a naturopathic alternative to antibiotics in treatment of minor burns.	2002-02	11890438
Deep partial thickness burn after contact with a Meal Ready-To-Eat heater.	2002-02	11873544
Effect of sulphadiazine and trimethoprim on the immune response of rainbow trout (Oncorhynchus mykiss).	2002-02	11867171
Safety and efficacy of an improved antiseptic catheter impregnated intraluminally with chlorhexidine.	2002-01-05	11758265
A novel kind of antitumour drugs using sulfonamide as parent compound.	2002-01-05	11755229
[Treatment of subclinical congenital toxoplasmosis by sulfadiazine and pyrimethamine continuously during 1 year: apropos of 46 cases].	2002-01	11865553
Effects of silver sulphadiazine on the production of exoproteins by Staphylococcus aureus.	2002-01	11800472
Antimicrobial-impregnated central venous catheters.	2002-01	11791103
Evaluation of an antimicrobial-impregnated continuous ambulatory peritoneal dialysis catheter for infection control in rats.	2002-01	11774116
Atypical anterior optic neuropathy caused by toxoplasmosis.	2002-01	11755864
Effect of sulfadiazine and pyrimethamine on selected physiologic and performance parameters in athletically conditioned thoroughbred horses during an incremental exercise stress test.	2002	12050828
The beneficial toxicity paradox of antimicrobials in leg ulcer healing impaired by a polymicrobial flora: a proof-of-concept study.	2002	12011525
Determination of selected sulfonamide antibiotics and trimethoprim in manure by electrospray and atmospheric pressure chemical ionization tandem mass spectrometry.	2002	11921244
[A case of primary pyoderma-like aspergillosis occurring in a patient with a cervical spinal cord injury].	2002	11865295
Matrix solid-phase dispersion extraction and high-performance liquid chromatographic determination of residual sulfonamides in chicken.	2001-12-07	11765084
[Drug hypersensitivity syndrome rapidly resolving after human immunoglobulin infusion].	2001-12	11908145
Bullous eruptions caused by extravasation of mannitol--a case report.	2001-12	11840587
Efficacy of antiadhesive, antibiotic and antiseptic coatings in preventing catheter-related infections: review.	2001-12	11806619
Retrospective analysis of drug-induced urticaria and angioedema: a survey of 2287 patients.	2001-11	11792017
Management of pressure ulcers.	2001-11	11758876
In vitro and in vivo efficacy of catheters impregnated with antiseptics or antibiotics: evaluation of the risk of bacterial resistance to the antimicrobials in the catheters.	2001-10	11776351
[New trends in ocular toxoplasmosis--the review].	2001	11921736

Patents

Sample Use Guides

In Vivo Use Guide

Usual Adult Dose for Toxoplasmosis Toxoplasmic encephalitis: Initial dose: Pyrimethamine 200 mg orally once Maintenance dose: <60 kg: Sulfadiazine 1 g orally every 6 hours plus pyrimethamine 50 mg orally once a day. >=60 kg: Sulfadiazine 1500 mg orally every 6 hours plus pyrimethamine 75 mg orally once a day. In addition, leucovorin 10 to 20 mg/day orally (may increase up to 50 mg/day).

Route of Administration: Oral

In Vitro Use Guide

Sulfadiazine inhibited Pseudomonas aeruginosa with MIC 256 ug/mL

Substance Class	Chemical Created by `admin` on `Mon Mar 31 21:37:18 GMT 2025` Edited by `admin` on `Mon Mar 31 21:37:18 GMT 2025`
Record UNII	5FE7HP0JMG
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

SULFADIAZINE ZINC

Common Name

English

ZINC SULFADIAZINE

Preferred Name

English

Zinc Sulfadiazine [WHO-DD]

Common Name

English

BENZENESULFONAMIDE, 4-AMINO-N-2-PYRIMIDINYL-, ZINC SALT (2:1)

Common Name

English

Code System Code Type Description

PUBCHEM

152849

Created by admin on Mon Mar 31 21:37:18 GMT 2025 , Edited by admin on Mon Mar 31 21:37:18 GMT 2025

PRIMARY

FDA UNII

5FE7HP0JMG

Created by admin on Mon Mar 31 21:37:18 GMT 2025 , Edited by admin on Mon Mar 31 21:37:18 GMT 2025

PRIMARY

CAS

69858-60-2

Created by admin on Mon Mar 31 21:37:18 GMT 2025 , Edited by admin on Mon Mar 31 21:37:18 GMT 2025

PRIMARY

Related Record Type Details


					13S1S8SF37

ZINC CATION

PARENT -> SALT/SOLVATE


					0N7609K889

SULFADIAZINE

PARENT -> SALT/SOLVATE

Related Record Type Details


					0N7609K889

SULFADIAZINE

ACTIVE MOIETY

AE	Significance	Dose	Population
Malaise	23%	4 g 1 times / day steady, oral Recommended Dose: 4 g, 1 times / day Route: oral Route: steady Dose: 4 g, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/12095805	unhealthy, 16 - 80 Health Status: unhealthy Age Group: 16 - 80 Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/12095805
Creatinine serum increased	5%	4 g 1 times / day steady, oral Recommended Dose: 4 g, 1 times / day Route: oral Route: steady Dose: 4 g, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/12095805	unhealthy, 16 - 80 Health Status: unhealthy Age Group: 16 - 80 Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/12095805
Diarrhea	5%	4 g 1 times / day steady, oral Recommended Dose: 4 g, 1 times / day Route: oral Route: steady Dose: 4 g, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/12095805	unhealthy, 16 - 80 Health Status: unhealthy Age Group: 16 - 80 Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/12095805
Elevated liver enzyme levels	5%	4 g 1 times / day steady, oral Recommended Dose: 4 g, 1 times / day Route: oral Route: steady Dose: 4 g, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/12095805	unhealthy, 16 - 80 Health Status: unhealthy Age Group: 16 - 80 Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/12095805
Thrombopenia	9%	4 g 1 times / day steady, oral Recommended Dose: 4 g, 1 times / day Route: oral Route: steady Dose: 4 g, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/12095805	unhealthy, 16 - 80 Health Status: unhealthy Age Group: 16 - 80 Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/12095805
Distress gastrointestinal	grade 3, 5% Disc. AE	4 g 1 times / day steady, oral Recommended Dose: 4 g, 1 times / day Route: oral Route: steady Dose: 4 g, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/12095805	unhealthy, 16 - 80 Health Status: unhealthy Age Group: 16 - 80 Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/12095805
Skin rash	grade 3, 5% Disc. AE	4 g 1 times / day steady, oral Recommended Dose: 4 g, 1 times / day Route: oral Route: steady Dose: 4 g, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/12095805	unhealthy, 16 - 80 Health Status: unhealthy Age Group: 16 - 80 Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/12095805
Stenocardia	grade 3, 5% Disc. AE	4 g 1 times / day steady, oral Recommended Dose: 4 g, 1 times / day Route: oral Route: steady Dose: 4 g, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/12095805	unhealthy, 16 - 80 Health Status: unhealthy Age Group: 16 - 80 Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/12095805
Febrile neutropenia	1.16%	1 g 4 times / day steady, oral Recommended Dose: 1 g, 4 times / day Route: oral Route: steady Dose: 1 g, 4 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/25411350	unhealthy, 29.81 Health Status: unhealthy Age Group: 29.81 Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/25411350
Skin rash	1.16%	1 g 4 times / day steady, oral Recommended Dose: 1 g, 4 times / day Route: oral Route: steady Dose: 1 g, 4 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/25411350	unhealthy, 29.81 Health Status: unhealthy Age Group: 29.81 Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/25411350
Neutropenia	18.75%	1 g 4 times / day steady, oral Recommended Dose: 1 g, 4 times / day Route: oral Route: steady Dose: 1 g, 4 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/25411350	unhealthy, 29.81 Health Status: unhealthy Age Group: 29.81 Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/25411350
Stevens Johnson syndrome	grade 3, 1.16% Disc. AE	1 g 4 times / day steady, oral Recommended Dose: 1 g, 4 times / day Route: oral Route: steady Dose: 1 g, 4 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/25411350	unhealthy, 29.81 Health Status: unhealthy Age Group: 29.81 Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/25411350
Major bleed	grade 4, 25% Disc. AE	1 g 4 times / day steady, oral Recommended Dose: 1 g, 4 times / day Route: oral Route: steady Dose: 1 g, 4 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/25411350	unhealthy, 29.81 Health Status: unhealthy Age Group: 29.81 Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/25411350
Thrombocytopenia	grade 4, 25% Disc. AE	1 g 4 times / day steady, oral Recommended Dose: 1 g, 4 times / day Route: oral Route: steady Dose: 1 g, 4 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/25411350	unhealthy, 29.81 Health Status: unhealthy Age Group: 29.81 Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/25411350
Skin rash	grade 3, 17.24% Disc. AE	6 g 1 times / day steady, oral Recommended Dose: 6 g, 1 times / day Route: oral Route: steady Dose: 6 g, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/1428784	unhealthy, 33.8 Health Status: unhealthy Age Group: 33.8 Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/1428784
Neutropenia	grade 3, 3.45% Disc. AE	6 g 1 times / day steady, oral Recommended Dose: 6 g, 1 times / day Route: oral Route: steady Dose: 6 g, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/1428784	unhealthy, 33.8 Health Status: unhealthy Age Group: 33.8 Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/1428784
Acute renal failure	grade 3, 6.9% Disc. AE	6 g 1 times / day steady, oral Recommended Dose: 6 g, 1 times / day Route: oral Route: steady Dose: 6 g, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/1428784	unhealthy, 33.8 Health Status: unhealthy Age Group: 33.8 Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/1428784

Details

SMILES

InChI

DescriptionSources: http://www.drugbank.ca/drugs/DB00359Curator's Comment: Description was created based on several sources, including https://www.drugs.com/dosage/sulfadiazine.html

CNS Activity

Originator

Approval Year

Targets

Conditions

Approved Use

Launch Date

Approved Use

Launch Date

Approved Use

Launch Date

Cmax

AUC

T1/2

Doses

AEs

Overview

OverviewOther

Drug as perpetrator​

Drug as victim

Sourcing

PubMed

Patents

Sample Use Guides

Description
Sources: http://www.drugbank.ca/drugs/DB00359
Curator's Comment: Description was created based on several sources, including https://www.drugs.com/dosage/sulfadiazine.html

C_max

T_1/2

Drug as perpetrator